WellsSA, AsaSL, DralleH, et al.2015Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid2015;25:567-610; doi: 10.1089/thy.2014.0335.
2.
ItoY, MiyauchiA, YabutaT, et al.Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: Experience of a single institution. World J Surg2009;33(1):58-66; doi.org/10.1007/s00268-008-9795-2.
3.
ShiX, ShenC, LiuC, et al.Hemithyroidectomy versus total thyroidectomy for sporadic medullary thyroid cancer: A Chinese nationwide large-scale cohort study. J Natl Compr Cancer Netw2025;23(3):105-112; doi.org/10.6004/jnccn.2024.7088.
4.
MiyauchiA, MatsuzukaF, HiraiK, et al.Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg2002;26(8):1023-1028; doi.org/10.1007/s00268-002-6665-1.
5.
CappagliV, MatroneA, BotticiV, et al.Multifocality and bilaterality in medullary thyroid cancer: Basis for a proof-of-concept safety of lobectomy. Eur Thyroid J2025;14(5):e250074; doi: 10.1530/ETJ-25-0074.
6.
WirthLJ, ShermanE, RobinsonB, et al.Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med.2020;383(9):825-835; doi: 10.1056/NEJMoa2005651.
7.
GildML, Clifton-BlighRJ, WirthLJ, et al.Medullary Thyroid Cancer: Updates and Challenges. Endocr Rev.2023 Sep 15;44(5):934-946; doi: 10.1210/endrev/bnad013.
